Genetic Engineering in Combination with Semi-Synthesis Leads to a New Route for Gram-Scale Production of the Immunosuppressive Natural Product Brasilicardin A.

Genetic Engineering in Combination with Semi-Synthesis Leads to a New Route for Gram-Scale Production of the Immunosuppressive Natural Product Brasilicardin A.
复制标题

DOI:
10.1002/anie.202015852
复制
发表时间:
2021-06-07
期刊:
Angewandte Chemie (International ed. in English)
影响因子:
--
通讯作者:
Gross H
Gross H
中科院分区:
其他
文献类型:
--
作者:
Botas A;Eitel M;Schwarz PN;Buchmann A;Costales P;Núñez LE;Cortés J;Morís F;Krawiec M;Wolański M;Gust B;Rodriguez M;Fischer WN;Jandeleit B;Zakrzewska-Czerwińska J;Wohlleben W;Stegmann E;Koch P;Méndez C;Gross H

文献摘要

参考文献

被引文献

相似文献

Brasilicardin A(1)由一个不寻常的具有碳水化合物侧链和氨基酸片段的抗/syn/抗过氢菲骨架组成。它显示出有效的免疫抑制活性,但其作用方式不同于目前使用的标准药物。这种有前景的、具有生物活性的天然产物的进一步临床前评估受到了现有材料的限制,因为它的合成既需要使用病原生物的低产量发酵过程,也需要复杂的、多步骤的全合成。我们的半合成方法包括:a)在不同的非致病细菌菌株中异种表达巴西卡丁素a基因簇,以优异的产量生产巴西卡丁素a苷元(5);b)通过简短而直接的五步合成路线,将苷元5化学转化为巴西卡丁素a (1a)的三氟乙酸盐。此外,我们报告了巴西绿素A的第一个临床前数据。介绍了一种能够以优异的速率可持续生产立体化学复杂天然产物巴西木苷C和E的异源生产菌株的开发。半合成方法允许将巴西绿ardin E有效地转化为有效的免疫抑制剂巴西绿ardin A,这是第一个临床前数据报告。
Brasilicardin A (1) consists of an unusual anti/syn/anti‐perhydrophenanthrene skeleton with a carbohydrate side chain and an amino acid moiety. It exhibits potent immunosuppressive activity, yet its mode of action differs from standard drugs that are currently in use. Further pre‐clinical evaluation of this promising, biologically active natural product is hampered by restricted access to the ready material, as its synthesis requires both a low‐yielding fermentation process using a pathogenic organism and an elaborate, multi‐step total synthesis. Our semi‐synthetic approach included a) the heterologous expression of the brasilicardin A gene cluster in different non‐pathogenic bacterial strains producing brasilicardin A aglycone (5) in excellent yield and b) the chemical transformation of the aglycone 5 into the trifluoroacetic acid salt of brasilicardin A (1 a) via a short and straightforward five‐steps synthetic route. Additionally, we report the first preclinical data for brasilicardin A. The development of a heterologous producer strain that enables the sustainable production of the stereochemically complex natural products brasilicardin C and E at excellent rates is presented. The semi‐synthetic approach allows an efficient gram‐scale conversion of brasilicardin E into the potent immunosuppressant brasilicardin A for which the first preclinical data are reported.
DOI: 10.1021/jo9807114
发表时间: 1998-10-02
影响因子: 3.6
作者:
Shigemori, H;Komaki, H;Kobayashi, J
通讯作者: Kobayashi, J
DOI: 10.1021/acs.jafc.0c04307
发表时间: 2020-09-30
影响因子: 6.1
作者:
Lim, Hyeonbae;Park, Jaehyun;Woo, Han Min
通讯作者: Woo, Han Min
DOI: 10.1007/s10637-020-00924-3
发表时间: 2020-03-20
影响因子: 3.4
作者:
Okano, Naohiro;Naruge, Daisuke;Furuse, Junji
通讯作者: Furuse, Junji
DOI: 10.1016/j.bmc.2004.08.007
发表时间: 2004-11-01
影响因子: 3.5
作者:
Komatsu, K;Tsuda, M;Kobayashi, J
通讯作者: Kobayashi, J
DOI: 10.1016/j.chembiol.2006.09.006
发表时间: 2006-11-01
影响因子: --
作者:
Usui, Takeo;Nagumo, Yoko;Osada, Hiroyuki
通讯作者: Osada, Hiroyuki